). One group of mice was injected with saline and another served as control. Three mice from each group were bled 1, 3, 6 and 9 hours post-injection, the blood was pooled and the nitrite serum levels, reflecting NO concentration, were determined using Greiss reagent. The following results were obtained: 1) Treatment with saline did not induce NO production; 2) LPS induced NO production to a maximal limit of 545% at 9 hours as compared to treatment with saline; 3) PGN did not induce NO production; 4) Nebivolol at most doses and periods (7 out of 10 determinations) increased NO production over a range of 18-110% as compared to treatment with saline; 5) Nebivolol enhanced LPS-induced production of NO by 58% at a dose of 0.7 µg/gm at 9 hours. It is concluded that nebivolol induces NO production. At low doses nebivolol initially appeared to have a suppressive or no effect on NO production induced by LPS. Increase in the dose of nebivolol resulted in augmentation of LPS-induced production of NO. PGN, in the dose tested, did not have an effect on NO production.
INTRODUCTION
Since the early report by Furchgott and Zawadzki in 1980 that the endothelium produces a vasodilator substance, initially referred to as the endothelium-derived relaxing factor, later demonstrated to be NO, extensive research revealed that NO was a short-lived mediator of numerous physiological as well as pathophysiological phenomena [1] . NO is synthesized by vascular endothelium, macrophages, neutrophils, Kupffer cells, brain cells and other cell types through the enzymatic effect of NO synthase on L-arginine [2] . NO, a very small lipophilic molecule with an ultra short half-life less than 5 seconds in biological tissues is a pleiotropic molecule that is indispensable for various physiological functions [3] . In the vascular bed, NO is a prominent vasodilator that relaxes smooth muscle, a potent inhibitor of platelet aggregation, and a major mediator of proliferation of vascular smooth muscle and endothelial cells via a cyclic GMP-independent mechanism [4] [5] [6] . Furthermore, some studies showed that NO reduces cardiomyocyte apoptosis and oxygen consumption despite reduced blood flow in patients [7, 8] . NO is a mediator of defense mechanisms including its cytotoxic role against foreign cells through functional disruption, and in tumor cells through DNA damage and p53 accumulation. However, elevated NO levels have deleterious effects. NO leads to increased pain perception through stimulation of pain-mediating sensory nerves, overproduction of peroxynitrite with negative effects on proteins and cell function, S-nitrosylation of proteins such as transcription factors, signaling kinases, ion channels and TGF-β, which elicits conformational modifications leading to loss of function [9] [10] [11] [12] .
Peptidoglycan (PGN), a constituent of the bacterial cell wall, is a polymer of N-acetylglucosamine and Nacetylmuramic acid residues. Lipopolysaccharide (LPS) is an amphipathic component of Gram-negative bacterial outer membrane consisting of 3 parts: the O-antigen (O-polysaccharide), the core polysaccharide and lipid A [13] . Both LPS and PGN are believed to contribute to hypotension and shock in bacteremias. PGN engages Toll-like receptor 2 (TLR2) and activates the myeloid differentiation factor 88 (MyD88)-independent pathway and LPS engages TLR4 that results in activation of both the MyD88-dependent and independent pathways. Both pathways lead eventually to an inflammatory response, mainly through the production of pro-inflammatory cytokines and inducible nitric oxide synthase (iNOS) [14] [15] [16] .
Nebivolol is a novel third generation β1-adrenoceptor blocker [17] [18] [19] advocated for the treatment of hypertension. It is unique among all β1-adrenoceptor blockers in that it possesses a vasodilatory property attributed to synthesis of NO [20, 21] as well as to increasing NO bioavailability by decreasing the oxidative stress [22] [23] [24] [25] [26] . In addition, Ladage et al. [27] reported that the endothelium-dependent increase in NO induced by nebivolol was due to stimulation of β 3 -adrenoceptors and estrogen receptors. Clinically, nebivolol has been shown to protect the heart from ischemia, arrhythmia and myocardial infarction through NO, including limiting oxygen consumption and maintaining cardiac contraction even with a reduced blood flow, in addition to minimizing cardiomyocyte apoptosis [28] [29] [30] .
In bacteremias, bacterial cells release some of their constituents such as LPS, lipoteichoic acid and PGN. These constituents stimulate a number of cell types to produce NO. The current study was undertaken to explore the effect of nebivolol on PGN-and LPS-induced NO production, reflected by determination of serum nitrite concentration.
MATERIALS AND METHODS

Study Protocol
Experiments were performed on 132 female BALB/c mice divided into 10 groups of 12 mice each and 2 groups of 6 mice each, treated with intraperitoneal injections of either saline, LPS, PGN, nebivolol or combinations as summarized in Table 1 . All the groups of mice, except groups 7 and 10, were bled 1, 3, 6 and 9 hours post-treatment. Prior to bleeding, mice were anesthetized by an intraperitoneal injection of ketamine and xylazine. The blood of 3 mice from each group at each time interval was pooled, allowed clotting and the serum was separated and stored at 4°C for nitrate/nitrite measurement. Groups 7 and 10 were bled at 6 and 9 hours post-treatment. Serum concentration of nitric oxide was indirectly measured using the Greiss reagent which determines the concentration of nitrite (NO 2
−
) and the nitrate (NO 3 − ), the final breakdown products of nitric oxide. The Greiss reagent was used according to the manufacturer's instructions (Sigma Chemicals co., MO, USA). NO has an ultra short half-life in blood that does not exceed 5 seconds. It dissociates into two final end products, namely nitrite (NO 2 − ) and nitrate (NO3 − ). Greiss reagent changes nitrates to nitrites and measures the nitrite concentration through a colorimetric reaction, the concentration of nitrite reflecting the concentration of NO. Spectrophotometric readings were done at a wavelength 490nm using a microplate reader. Assays for the determination of nitrate and nitrite were run twice as each sample of blood was pooled from 3 mice that received the same treatment at the same time interval. The average of the two determinations was taken as a reflection of NO concentration and the standard deviation of the two determinations was calculated indicated reproducibility of the analysis. Comparisons between different groups of mice and at different time intervals were considered significant when there was no overlap between the means and standard deviations.
Drugs and Reagents Used
LPS from Salmonella enterica serovar Minnesota (Sigma Chemicals co., MO, USA, prepared as suspendsion of 30 µg/0.5 ml); PGN from Bacillus subtilis (Sigma Chemicals co., MO, USA, prepared as a suspension of 100 µg/0.5 ml); nebivolol (Cipla, India, prepared as dilutions of 0.25 µg/g-0.7 µg/g); ketamine (Panpharma, France, prepared as dilution of 6 mg/0.5 ml); xylazine (Interchemie, Holland, prepared as dilution of 0.6 mg/0.5 ml); Greiss reagent (Sigma Chemicals co., MO, USA). Chemicals were dissolved in pyrogen free saline, except for the anesthetics which were dissolved in pyrogen free water. All solvents were confirmed pyrogen free by the Limulus Amebocyte Lysate (LAL) test.
RESULTS
The changes in the serum concentration of nitrites (µmole/l) in response to various treatments and time intervals are summarized in Table 2 .
Untreated and Saline-Treated Groups of Mice
NO levels in mice that were untreated or injected with saline were approximately the same ( Table 2) .
Group of Mice Treated with Nebivolol
Out of 10 assays in different doses at different time intervals, nebivolol increased the nitrate/nitrite production in 7 assays over a range of 18-170% as compared to saline treated group (Tables 2,3, Figure 1 ).
Group of Mice Treated with LPS Alone
As compared to the saline-treated group, there was an increase with nitrate/nitrite concentration of 93%, 71%, 356% and 545% at time intervals 1, 3, 6 and 9 hours respectively (Tables 2,4, Figure 2 ).
Group of Mice Treated with PGN Alone
PGN had an inconsistent effect on nitrate/nitrite production ranging from −27% to +29% at various time intervals, as compared to saline treated group. (Tables 2,  4, Figure 2 ).
Group of Mice Treated with LPS + Nebivolol
Out of 10 assays in different doses at different time intervals, there was a decrease or no change in nitrate/ nitrite production in 9 assays, ranging from −4% to −65% as compared to respective values in response to treatment with LPS alone. However, at a dose of nebivolol of 0.7 µg/gm and an interval of 9 hours, there was an increase in nitrate/nitrite production of 58% as compared to the respective value after treatment with LPS alone, implying that LPS-induced NO production is inhibited by nebivolol in lowest doses at short intervals of exposure and is potentiated at high doses and long interval of exposure (Tables 2,5, Figure 3 ).
Groups of Mice Treated with PGN + Nebivolol
Treatment with nebivolol in different doses and at different intervals produced an inconsistent effect of PGN-induced effect on nitrate/nitrite production varying from no change in two assays, a decrease of −13% to −18% in two assays and an increase in four assays of Serum nitrite concentrations were analyzed in duplicate and the average of the two determinations was taken as a reflection of NO concentration and the standard deviation of the two determinations indicated reproducibility of the analysis. LPS: lipopolysaccharide; PGN: peptidoglycan; n: nebivolol; ND: not determined. Figure 1 . Nitrite levels, reflecting NO levels, at 1, 3, 6 and 9 hours after injection with either saline or nebivolol (n). Columns represent mean of duplicate analysis and the bars standard deviation of the duplicate analysis. Differences between concentrations of nitrite were considered significant when the means and the standard deviations did not overlap. n: nebivolol. 
DISCUSSION
Nebivolol is a novel third generation β1-adrenoceptor blocker [17] [18] [19] [20] advocated for the treatment of hypertension. It is unique among all β1-adrenoceptor blockers in that it possesses a vasodilatory property attributed to synthesis of NO [21, 22] as well as to increasing NO bioavailability by decreasing the oxidative stress [23] [24] [25] [26] [27] . The observation that nebivolol increases the concentration of nitrite in 7 out of 10 as-says using different doses and at different time intervals, reflecting an increase in the NO levels, is confirmatory to observations reported by others [31] [32] [33] .
LPS and PGN have been associated with increased production of NO during sepsis, where NO has been a major contributor to vascular collapse, a major cause of mortality in septic shock cases [34, 35] . LPS but not PGN induced NO synthesis. This can be attributed partly to the different signaling pathways induced by each. There are at least two pathways that LPS activates, both of which lead to the production of NO. In the first, LPS engages TLR4 expressed by macrophages and neutronphils. As a result 2 intracellular signaling pathways, the MyD88-dependent and independent pathways are activated and lead to the production of pro-inflammatory cytokines and NO [36] [37] [38] [39] [40] . In the second pathway, LPS induces the production of gamma interferon which in turn interacts with its receptor expressed on several cell types [41] . The intracellular events that follow lead to the activation of the transcription factor, IRF-1, and production of NO. In support of these results, previous studies have shown that LPS, rather than PGN, induced effectively the cytokine expression machinery (TNF-α, IL-1 α, IL-12, IL-23, IFN-γ, CCL-2, CCL-5) 3 hours after LPS treatment shifting to a Th1 response as evidenced by the high IFN-γ/IL-4 ratio and by the immense delayed type hypersensitive response, while PGN favored the Th2 type [42] . Moreover, Fahmi et al. [43] have shown that lipoteichoic acid rather than PGN is the potent inducer of NO upon severe infection with Grampositive bacteria and that PGN augmented the lipoteichoic acid-NO inducing activity. It is worth noting that Ida et al. [44] reported that propanolol, a beta adrenergic receptor antagonist, did not influence cytokine release by lipoteichoic acid.
Nebivolol at doses 0.25 and 0.35 µg/g given in combination with LPS had no, or a suppressive effect on NO production induced by LPS. Arai et al. [45] reported that beta adrenergic receptor antagonists (ICI-188551, betaxolol, timolol and metipranolol) did not influence NO production induced by LPS. However, nebivolol at a dose 0.7 µg/g potentiated NO production induced by LPS at 9 hours post-injection, implying that the effect of nebivolol on LPS-induced NO production is dose and time-dependent. These results could in part be explained by the study of Broeder et al. [18] who reported that nebivolol does not induce the production of NO. Rather, its metabolites do so. It appears that a time factor is involved, taking about 9 hours for the production of metabolites which contribute to the delayed effect of nebivolol. It can be hypothesized that intact nebivolol has a suppressive effect on NO production induced by LPS, and its metabolites that take about 9 hours to be formed enhance NO production induced by LPS. Understanding the relationship between nebivolol and PGN on NO production machinery is complex due to the interrelationships among NO induction pathways. Some studies have indicated that beta blockers do not interact through the MyD88-dependent or the MyD88-independent pathways and that the MyD88-dependent pathway that leads to NO production after PGN engages TLR2, is unaffected by the administration of beta blockers [46] . Other findings have shown that beta blockers affect PGN through other PGN recognition receptors such as CD14, nucleotide oligomerization domain (Nod)-containing proteins, a family of PGN recognition proteins, and
